Almenoff June Sherie — SEC Form 4 filings
SEC reporting owner CIK 1492647. 12 Form 4 filings on record with FilingPulse; latest filed 2026-09-04.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-08-14 to 2026-09-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 6 legs across 3 filings — 4,986 shares, $42,639 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 12.
- Largest priced transaction: purchase of 1,900 shares @ $7.52 ($14,280) in TENAX THERAPEUTICS, INC., filed 2025-11-20.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | Director | 5 | 4 legs · 3,986 sh · $29,890 | — | 3 |
| Avalo Therapeutics, Inc. (AVTX) | Director | 4 | 2 legs · 1,000 sh · $12,750 | — | 5 |
| Actinium Pharmaceuticals, Inc. (ATNM) | Director | 3 | — | — | 4 |
Form 4 filings — Almenoff June Sherie
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-04 | 4 | Actinium Pharmaceuticals, Inc. (ATNM) | Grant/award (A): 18,000 @ $0 · Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | TENAX THERAPEUTICS, INC. (TENX) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-11-20 | 4/A | TENAX THERAPEUTICS, INC. (TENX) | Purchase (P): 93 @ $7.15 · Purchase (P): 1,900 @ $7.52 | EDGAR |
| 2025-11-19 | 4 | TENAX THERAPEUTICS, INC. (TENX) | Purchase (P): 93 @ $7.15 · Purchase (P): 1,900 @ $7.52 | EDGAR |
| 2025-07-03 | 4 | TENAX THERAPEUTICS, INC. (TENX) | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 20,100 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | Actinium Pharmaceuticals, Inc. (ATNM) | Disposition to issuer (D): 50,000 (derivative) @ $0 | EDGAR |
| 2025-04-01 | 4 | Avalo Therapeutics, Inc. (AVTX) | Option exercise (M): 3,167 · Option exercise (M): 3,167 (derivative) @ $0 | EDGAR |
| 2024-12-12 | 4 | TENAX THERAPEUTICS, INC. (TENX) | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-11-14 | 4 | Avalo Therapeutics, Inc. (AVTX) | Purchase (P): 500 @ $12.50 · Purchase (P): 500 @ $13 | EDGAR |
| 2024-11-05 | 4 | Actinium Pharmaceuticals, Inc. (ATNM) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-08-14 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 24,600 (derivative) @ $0 · Grant/award (A): 9,500 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1492647 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →